title: Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus.
abstract: Cutaneous lupus erythematosus (CLE) is characterized by enhanced interferon α (IFNα) levels in serum and in tissue. Since IFNα promotes a Th1-biased immune response, we hypothesized that a Th1-associated chemokine receptor profile should be a typical finding in patients with active CLE. Therefore, peripheral blood mononuclear cells were isolated from patients with different CLE subsets (n = 15), healthy controls (n = 13) and patients under immunotherapy with IFNα (n = 7). T helper cells were analysed by flow cytometry for the expression of the chemokines receptor CCR5, indicative for Th1 cells, and of CCR3, indicating Th2. In addition, intracellular levels of the type I IFN-inducible MxA protein were measured. Patients with widespread active CLE skin lesions had a significantly increased expression of CCR5, whereas expression of CCR3 was decreased when compared with healthy controls. MxA expression was significantly enhanced in all investigated CLE subtypes, with the highest levels in patients with widespread skin lesions. The enhanced CCR5/CCR3 ratio closely correlated with the MxA levels in peripheral lymphocytes and with disease activity. Our analyses revealed that active CLE is associated with a systemic type I IFN effect that appears to induce a shift towards a Th1-associated chemokine receptor profile. The CCR5/CCR3 T-helper cell ratio might therefore represent an indirect marker for the disease activity in CLE.
authors.affiliation: Department of Dermatology and Allergy, University of Bonn, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Freutel
authors.forename: E
authors.initials: E
authors.lastname: Gaffal
authors.forename: S
authors.initials: S
authors.lastname: Zahn
authors.forename: T
authors.initials: T
authors.lastname: Bieber
authors.forename: T
authors.initials: T
authors.lastname: Tüting
authors.forename: J
authors.initials: J
authors.lastname: Wenzel
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D019204:GTP-Binding Proteins / Q000097:blood; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008179:Lupus Erythematosus, Discoid / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D064547:Myxovirus Resistance Proteins; D054397:Receptors, CCR3 / Q000097:blood; D019713:Receptors, CCR5 / Q000097:blood; D018417:Th1 Cells / Q000276:immunology* / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism; D055815:Young Adult
chemical_list: C515350:CCR3 protein, human; D016898:Interferon-alpha; C579071:MX1 protein, human; D064547:Myxovirus Resistance Proteins; D054397:Receptors, CCR3; D019713:Receptors, CCR5; D019204:GTP-Binding Proteins